CRISPR Therapeutics AG (NASDAQ: CRSP) stock jumped 6.32% on Monday to $72.18 against a previous-day closing price of $67.89. With 8.01 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.5 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $76.19 whereas the lowest price it dropped to was $68.10. The 52-week range on CRSP shows that it touched its highest point at $72.00 and its lowest point at $37.55 during that stretch. It currently has a 1-year price target of $87.78. Beta for the stock currently stands at 1.79.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRSP was up-trending over the past week, with a rise of 38.78%, but this was up by 81.45% over a month. Three-month performance surged to 50.59% while six-month performance rose 16.18%. The stock gained 22.84% in the past year, while it has gained 77.56% so far this year. A look at the trailing 12-month EPS for CRSP yields -4.48 with Next year EPS estimates of -6.61. For the next quarter, that number is -0.25. This implies an EPS growth rate of 58.42% for this year and -90.18% for next year.
Float and Shares Shorts:
At present, 78.51 million CRSP shares are outstanding with a float of 76.26 million shares on hand for trading. On Oct 30, 2023, short shares totaled 13.89 million, which was 17.49% higher than short shares on Sep 28, 2023. In addition to Dr. Samarth Kulkarni Ph.D. as the firm’s CEO & Chairman, Mr. James R. Kasinger serves as its General Counsel & Secretary.
Through their ownership of 67.47% of CRSP’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 0.00% of CRSP, in contrast to 0.00% held by mutual funds. As the largest shareholder in CRSP with 0.00% of the stake, Carnegie Capital Asset Management holds 88,717 shares worth 88,717. A second-largest stockholder of CRSP, Yorkville Asset Management, Inc., holds 500 shares, controlling over 0.00% of the firm’s shares. U.S. Bank NA is the third largest shareholder in CRSP, holding 6,313 shares or 0.00% stake. With a 0.00% stake in CRSP, the American Funds New Perspective Fu is the largest stakeholder. A total of 3,550,544 shares are owned by the mutual fund manager. The American Funds Growth Fund of Ame, which owns about 0.00% of CRSP stock, is the second-largest Mutual Fund holder. It holds 798,191 shares valued at 0.0. Fidelity Select Port. – Biotechno holds 0.00% of the stake in CRSP, owning 242,822 shares worth 0.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRSP since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRSP analysts setting a high price target of $220.00 and a low target of $42.00, the average target price over the next 12 months is $87.78. Based on these targets, CRSP could surge 204.79% to reach the target high and fall by -41.81% to reach the target low. Reaching the average price target will result in a growth of 21.61% from current levels.
Summary of Insider Activity:
Insiders traded CRSP stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 28 over the past year. The total number of shares bought during that period was 333,654 while 221,626 shares were sold.